Corcept Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/28/2023
Corcept Therapeutics Stock Forecast and Price Target
If Corcept Therapeutics's stock price reached the average yearlong target of $29.50 given by well-known analysts in recent months, there would be a potential upside of approximately 23.02% from its last closing price in May, 2023. This potential increase is based on a high estimate of $35.00 and a low estimate of $16.00. If you are interested in CORT stock, it is important to also consider its competitors.
23.02% Upside
Corcept Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Corcept Therapeutics's Price has grown by 9.17%, rising from $19.05 to $20.80. 0 analysts predict Corcept Therapeutics's Fair Value will decrease by 3.40% in the next year, reaching $20.09. By 2030, professionals predict that Corcept Therapeutics's Fair Value will decrease by 3.16%, to $20.14.
Corcept Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Corcept Therapeutics's Revenue has grown by 19.41%, rising from $306.49M to $365.98M. 0 analysts predict Corcept Therapeutics's Revenue will decrease by 6.67% in the next year, reaching $341.57M. By 2030, professionals predict that Corcept Therapeutics's Revenue will decrease by 6.09%, to $343.68M.
.jpg)
Corcept Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030
Corcept Therapeutics's Free Cash Flow has seen impressive growth In the last two years, rising from $135.03M to $166.65M – a growth of 23.42%. The next year, 0 experts forecast that Corcept Therapeutics's Free Cash Flow will decrease by 9.84%, reaching $150.25M. In 2030, professionals predict that Corcept Therapeutics's Free Cash Flow will decrease by 8.97%, reaching $151.70M.
Corcept Therapeutics Net Income Forecast for 2023 - 2025 - 2030
Corcept Therapeutics's Net Income has grown In the last two years, rising from $94.18M to $112.51M – a growth of 19.46%. In the following year, the 0 analysts surveyed believe that Corcept Therapeutics's Net Income will decrease by 7.57%, reaching $103.99M. According to professionals, by 2030, Corcept Therapeutics's Net Income will have decreased by 6.94%, falling down to $104.70M.
Corcept Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Corcept Therapeutics's EBITDA has grown by 11.79%, rising from $112.31M to $125.55M. According to the 0 analysts polled, in the next year, Corcept Therapeutics's EBITDA will fall by 2.57%, reaching $122.33M. By 2030, professionals believe that Corcept Therapeutics's EBITDA will have decreased by 2.30%, falling to $122.66M.
Corcept Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Corcept Therapeutics's EBIT has grown, moving from $111.61M to $124.48M – an increase of 11.53%. For the next year, 0 analysts project Corcept Therapeutics's EBIT to drop by 2.32%, reaching $121.59M. By 2030, professionals believe that Corcept Therapeutics's EBIT will decrease by 2.05%, reaching $121.92M – a concerning trend for the company.
Corcept Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Corcept Therapeutics's EPS has grown by 9.17%, rising from $1.09 to $1.19. 0 analysts predict Corcept Therapeutics's EPS will decrease by 3.40% in the next year, reaching $1.15. By 2030, professionals predict that Corcept Therapeutics's EPS will decrease by 3.16%, to $1.15.
Site Navigation
.jpg)